AI in Rare Disease Diagnostics Market
完整報告名稱與涵蓋範圍
AI in Rare Disease Diagnostics Market Size, Share & Trends Analysis Report, By Solution Type (AI-Enabled Genomic Variant Interpretation and Prioritization, Phenotype-Based and Facial Recognition Diagnostic Tools, Electronic Health Record Screening and Patient Identification Algorithms, Integrated Rare Disease Diagnostic Services and Platforms), By Deployment (Cloud-Based, On-Premise and Hybrid), By End User (Genetic Testing Laboratories, Hospitals, Children's Hospitals and Rare Disease Centers, Pharmaceutical Companies and Patient Identification Programs, Research Institutions and Undiagnosed Disease Programs), By Region, and Segment Forecasts, 2026-2035
報告摘要
The AI in rare disease diagnostics market covers software and services that apply machine learning to genomic variant interpretation and prioritisation, phenotype and facial feature analysis, electronic health record screening for undiagnosed patients and integrated rare disease diagnostic platforms, serving genetic laboratories, hospitals, pharmaceutical patient identification programs and research centers. Sequencing instruments, reagents and wet-lab genetic testing services without AI components are excluded.
The diagnostic odyssey for rare disease patients averages several years, and AI is compressing it at every step: variant interpretation tools rank candidate variants from exome and genome data in minutes, phenotype-driven algorithms match clinical features to thousands of disorders, facial analysis recognises syndromic patterns and record-screening models flag patients whose histories suggest an undiagnosed condition. Demand is driven by falling sequencing costs and rapid genome programs in neonatal intensive care, by the growing number of approved rare disease therapies that make diagnosis actionable, by pharmaceutical companies funding patient identification and by health system programs that reanalyse unsolved cases. Regulatory classification of interpretation software, data sharing across institutions, validation across ancestries and reimbursement for genomic testing shape adoption.
North America and Europe lead, with the United Kingdom, France and the Nordic countries running national genomic programs and China, Japan and the Middle East expanding rare disease initiatives. Competition involves genetic testing leaders, clinical genomics software specialists, phenotype AI companies and pharmaceutical-funded patient finding platforms.
The InsightAce study delivers revenue forecasts in US$ across all solution type, deployment and end user and regional segments for 2026-2035, alongside segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global AI in Rare Disease Diagnostics Market Snapshot
Chapter 4. Global AI in Rare Disease Diagnostics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Solution Type Estimates & Trend Analysis
5.1. Solution Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Solution Type:
5.2.1. AI-Enabled Genomic Variant Interpretation and Prioritization
5.2.2. Phenotype-Based and Facial Recognition Diagnostic Tools
5.2.3. Electronic Health Record Screening and Patient Identification Algorithms
5.2.4. Integrated Rare Disease Diagnostic Services and Platforms
Chapter 6. Market Segmentation 2: By Deployment Estimates & Trend Analysis
6.1. Deployment & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Deployment:
6.2.1. Cloud-Based
6.2.2. On-Premise and Hybrid
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. End User & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
7.2.1. Genetic Testing Laboratories
7.2.2. Hospitals, Children's Hospitals and Rare Disease Centers
7.2.3. Pharmaceutical Companies and Patient Identification Programs
7.2.4. Research Institutions and Undiagnosed Disease Programs
Chapter 8. AI in Rare Disease Diagnostics Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. GeneDx Holdings Corp.
10.2. Illumina, Inc.
10.3. QIAGEN N.V.
10.4. SeqOne Genomics
10.5. SOPHiA GENETICS SA
10.6. Nostos Genomics GmbH
10.7. FDNA Inc.
10.8. Mendelian Ltd.
10.9. Saventic Health sp. z o.o.
10.10. Volv Global SA
10.11. Fabric Genomics, Inc.
10.12. Emedgene (Illumina)
10.13. Congenica Ltd.
10.14. Genomenon, Inc.
10.15. Alexion (AstraZeneca plc) Patient Finding Programs
圖表清單 List of Tables & Figures
Table 1. Global AI in Rare Disease Diagnostics Market Revenue Forecast by Solution Type, 2026-2035 (US$ Mn)
Figure 1. Global AI in Rare Disease Diagnostics Market Segmentation and Scope Overview
Table 2. Global AI in Rare Disease Diagnostics Market Revenue Forecast by Deployment, 2026-2035 (US$ Mn)
Figure 2. Global AI in Rare Disease Diagnostics Market Share by Solution Type, 2026 & 2035
Table 3. Global AI in Rare Disease Diagnostics Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 3. AI-Enabled Rare Disease Diagnostic Pathway from Phenotype Capture to Variant Interpretation
Table 4. Global AI in Rare Disease Diagnostics Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 4. Rapid Genome Sequencing Programs and Diagnostic Yield Improvements by Region
Table 5. North America AI in Rare Disease Diagnostics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific AI in Rare Disease Diagnostics Growth Opportunity Analysis
Table 6. Europe AI in Rare Disease Diagnostics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key AI in Rare Disease Diagnostics Market Participants
Table 7. Asia Pacific AI in Rare Disease Diagnostics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global AI in Rare Disease Diagnostics Market
Table 8. Strategic Developments of Leading AI in Rare Disease Diagnostics Market Participants, 2023-2026
Figure 8. Pharmaceutical Patient Identification Programs and Their Role in Diagnostic Software Demand
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們